Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells

Oncogene

Volumn 36, Issue 37, 2017, Pages 5231-5242

  Kawauchi, D ^a,b   Ogg, R J ^a   Liu, L ^a   Shih, D J H ^c   Finkelstein, D ^a   Murphy, B L ^a   Rehg, J E ^a   Korshunov, A ^d   Calabrese, C ^a   Zindy, F ^a   Phoenix, T ^a   Kawaguchi, Y ^e   Gronych, J ^b   Gilbertson, R J ^a   Lichter, P ^b   Gajjar, A ^a   Kool, M ^b   Northcott, P A ^a   Pfister, S M ^b,f   Roussel, M F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FOURTH VENTRICLE; CELL PROLIFERATION; CEREBELLUM CELL; CONTROLLED STUDY; ELECTROPORATION; EMBRYO CELL; FEMALE; GABAERGIC SYSTEM; GENE EXPRESSION; GRANULE CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOLECULAR DYNAMICS; MOUSE; NEUROEPITHELIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR XENOGRAFT; ANIMAL; CEREBELLUM; CEREBELLUM TUMOR; CYTOLOGY; DISEASE MODEL; EMBRYOLOGY; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CEREBELLAR NEOPLASMS; CEREBELLUM; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; TRANSFECTION;

EID: 85030479503     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.110     Document Type: Article

References (58)

1. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-439.
2. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-105.
3. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012; 8: 340-351.
4. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol 2008; 3: 341-365.
5. Roussel MF, Hatten ME. Cerebellum development and medulloblastoma. Curr Top Dev Biol 2011; 94: 235-282.
6. Dastjerdi FV, Consalez GG, Hawkes R. Pattern formation during development of the embryonic cerebellum. Front Neuroanat 2012; 6: 10.
7. Wu X, Northcott PA, Croul S, Taylor MD. Mouse models of medulloblastoma. Chin J Cancer 2011; 30: 442-449.
8. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008; 14: 123-134.
9. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008; 14: 135-145.
10. Li P, Du F, Yuelling LW, Lin T, Muradimova RE, Tricarico R et al. A population of Nestin-expressing progenitors in the cerebellum exhibits increased tumorigenicity. Nat Neurosci 2013; 16: 1737-1744.
11. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468: 1095-1099.
12. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012; 21: 155-167.
13. Lorenz A, Deutschmann M, Ahlfeld J, Prix C, Koch A, Smits R et al. Severe alterations of cerebellar cortical development after constitutive activation of Wnt signaling in granule neuron precursors. Mol Cell Biol 2011; 31: 3326-3338.
14. Poschl J, Grammel D, Dorostkar MM, Kretzschmar HA, Schuller U. Constitutive activation of beta-catenin in neural progenitors results in disrupted proliferation and migration of neurons within the central nervous system. Dev Biol 2013; 374: 319-332.
15. Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 2012; 21: 601-613.
16. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012; 21: 168-180.
17. Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE et al. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 2007; 67: 2676-2684.
18. Roussel MF, Robinson GW. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med 2013; 3: a014308.
19. Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G et al. DiSCoVERing Innovative Therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets. Clin Cancer Res 2016; 22: 3903-3914.
20. Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 2014; 11: 714-722.
21. Khandanpour C, Phelan JD, Vassen L, Schutte J, Chen R, Horman SR et al. Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia. Cancer Cell 2013; 23: 200-214.
22. Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014; 511: 428-434.
23. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 2015; 27: 72-84.
24. Kawauchi D, Saito T. Transcriptional cascade from Math1 to Mbh1 and Mbh2 is required for cerebellar granule cell differentiation. Dev Biol 2008; 322: 345-354.
25. Sato Y, Kasai T, Nakagawa S, Tanabe K, Watanabe T, Kawakami K et al. Stable integration and conditional expression of electroporated transgenes in chicken embryos. Dev Biol 2007; 305: 616-624.
26. Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev 1996; 10: 826-835.
27. Yokota Y, Saito D, Tadokoro R, Takahashi Y. Genomically integrated transgenes are stably and conditionally expressed in neural crest cell-specific lineages. Dev Biol 2011; 353: 382-395.
28. Paxinos G, Franklin KB. The Mouse Brain in Stereotaxic Coordinates, 3rd edn. Academic Press: New York, NY, USA, 2008.
29. Hevner RF, Hodge RD, Daza RA, Englund C. Transcription factors in glutamatergic neurogenesis: conserved programs in neocortex, cerebellum, and adult hippocampus. Neurosci Res 2006; 55: 223-233.
30. Hoshino M, Nakamura S, Mori K, Kawauchi T, Terao M, Nishimura YV et al. Ptf1a, a bHLH transcriptional gene, defines GABAergic neuronal fates in cerebellum. Neuron 2005; 47: 201-213.
31. Wefers AK, Warmuth-Metz M, Poschl J, von Bueren AO, Monoranu CM, Seelos K et al. Subgroup-specific localization of human medulloblastoma based on preoperative MRI. Acta Neuropathol 2014; 127: 931-933.
32. Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D et al. MRI surrogates for molecular subgroups of medulloblastoma. Am J Neuroradiol 2014; 35: 1263-1269.
33. Cho KH, Rodriguez-Vazquez JF, Kim JH, Abe H, Murakami G, Cho BH. Early fetal development of the human cerebellum. Surg Radiol Anat 2011; 33: 523-530.
34. Sgaier SK, Millet S, Villanueva MP, Berenshteyn F, Song C, Joyner AL. Morphogenetic and cellular movements that shape the mouse cerebellum; insights from genetic fate mapping. Neuron 2005; 45: 27-40.
35. Cheng FY, Huang X, Sarangi A, Ketova T, Cooper MK, Litingtung Y et al. Widespread contribution of Gdf7 lineage to cerebellar cell types and implications for hedgehog-driven medulloblastoma formation. PLoS One 2012; 7: e35541.
36. Hunter NL, Dymecki SM. Molecularly and temporally separable lineages form the hindbrain roof plate and contribute differentially to the choroid plexus. Development 2007; 134: 3449-3460.
37. Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun 2015; 6: 7391.
38. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159: 440-455.
39. Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005; 19: 2656-2667.
40. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3: e3088.
41. Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S et al. Silencing of the miR-17-92 cluster family inhibits medulloblastoma progression. Cancer Res 2013; 73: 7068-7078.
42. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-425.
43. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457: 603-607.
44. Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014; 25: 393-405.
45. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009; 218: 86-94.
46. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-48.
47. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999; 7: 254-266.
48. Brett M. The MNI brain and the Talairach Atlas. Neuroimaging Laboratory: Washington University, St Louis, CA, USA, 2005.
49. Evans AC, Collins DL, Mills SR, Brown ED, Kelly RL, Peters TM 3D Statistical Neuroanatomical Models from 305 MRI Volumes. Proceedings of the IEEE-Nuclear Science Symposium and Medical Imaging Conference. 1993, pp 1813-1817.
50. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme: New York, NY, USA, 1988.
51. Schmahmann JD, Doyon J, Toga AW, Petrides M, Evans AC. MRI Atlas of the Human Cerebellum. Academic Press: San Diego, CA, USA, 2000.
52. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S et al. 3D Slicer as an Image Computing Platform for the Quantitative Imaging Network. Magnetic Resonance Imaging 2012; 30: 1323-1341.
53. Rogers HA, Ward JH, Miller S, Lowe J, Coyle B, Grundy RG. The role of the WNT/beta-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs). Br J Cancer 2013; 108: 2130-2141.
54. Birks DK, Donson AM, Patel PR, Sufit A, Algar EM, Dunham C et al. Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes. Pediatr Blood Cancer 2013; 60: 1095-1102.
55. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics 2010; 11: 242-253.
56. McCall MN, Jaffee HA, Zelisko SJ, Sinha N, Hooiveld G, Irizarry RA et al. The Gene Expression Barcode 3.0: improved data processing and mining tools. Nucleic Acids Res 2014; 42: D938-D943.
57. Liaw A, Wiener M. Classification and regression by randomForest. R News 2002; 2: 18-22.
58. Wiener ALaM. Classification and regression by randomForest. R News 2002; 2: 18-2.